FLT1 and melanoma: In the present study, we have investigated whether VEGFR‐1 might contribute to the acquisition of a BRAFi‐resistant phenotype by melanoma and whether blockade of this receptor might reduce ECM invasion by resistant tumour cells in response to angiogenic factors.